Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 EMD Serono Names U.S. CMO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

EMD Serono Names U.S. CMO

Leveque brings 20 years of industry experience

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Joseph Leveque, M.D. has been appointed U.S. chief medical officer at EMD Serono, the U.S. biopharmaceutical business of Merck KGaA. Dr. Leveque will be responsible for working with the regulatory, medical and development teams to enhance EMD Serono’s clinical presence in the U.S. and to drive key medical initiatives.
 
Dr. Leveque has more than 20 years of experience in the areas of strategic leadership, advancing medical and clinical programs, as well as life cycle management. Most recently, he served as head of U.S. Medical for Oncology at Bristol-Myers Squibb, where he was responsible for providing strategic leadership and management for marketed and near-term pipeline oncology assets. Dr. Leveque has also held medical affairs leadership positions at Onyx Pharmaceuticals, Inc., Cephalon and Amgen, Inc.
 
“Dr. Leveque’s substantial experience in managing integrated global medical affairs teams will be significant to furthering our specialty care focus in neurology, oncology, fertility, and endocrinology and bringing our pipeline forward,” said Paris Panayiotopoulos, president and managing director of EMD Serono. “In the U.S., Dr. Leveque will collaborate closely with our global medical and R&D organizations, and will play a key role in advancing our commitment to innovation and bringing new therapeutic options to patients, particularly those with difficult to treat diseases.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters